Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non–small cell lung cancer treated with nivolumab
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger… - JAMA …, 2019 - jamanetwork.com
Importance Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is
approved by the US Food and Drug Administration for treating advanced melanoma, renal
cell carcinoma (RCC), non–small cell lung cancer (NSCLC), and other malignancies. Data
on long-term survival among patients receiving nivolumab are limited. Objectives To analyze
long-term overall survival (OS) among patients receiving nivolumab and identify clinical and
laboratory measures associated with tumor regression and OS. Design, Setting, and …
approved by the US Food and Drug Administration for treating advanced melanoma, renal
cell carcinoma (RCC), non–small cell lung cancer (NSCLC), and other malignancies. Data
on long-term survival among patients receiving nivolumab are limited. Objectives To analyze
long-term overall survival (OS) among patients receiving nivolumab and identify clinical and
laboratory measures associated with tumor regression and OS. Design, Setting, and …